Skip to main content
SpringerLink
Log in

Some aspects of size-dependent differential drug response in primary and metastatic tumors

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Summary

The response of cancer to various anticancer drugs is tumor-size dependent in many aspects. In general, problems stem partly from the fact that the entire tumor cell populations do not respond equally to a certain treatment. As a result of recent progress in cancer biology, it has become evident that cellular heterogeneity of the tumor underlies the difficulties of treating primary and metastatic tumors with chemotherapy. Moreover, as tumors grow, marked diversity develops on the tissue level as well. An uneven distribution with an increase of areas of lower growth fraction and of poorer drug delivery is more distinct in larger tumors. Heterogeneous distribution and low levels of tumor blood flow are considered to be causally related to the heterogeneous nature of tumor tissue. Considering the lack of evidence of a lymphatic system within the tumor, increased interstitial fluid pressure may be a natural result that further impedes blood flow in the tumor. The fact that the temporary and selective increase in tumor tissue blood flow by angiotensin-induced hypertension produces a remarkable chemotherapeutic effect should vividly indicate that delivery of the drug to the tumor is really the ‘bottleneck’ of cancer chemotherapy. Tumor-size-related change in the transvascular and extravascular transport of molecules and its relevance to chemotherapy are also discussed in this article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bruce WR, Meeker BE, Valeriote FA: Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37: 233–245, 1966.

    Google Scholar 

  2. Bruce WR, Meeker BE, Powers WE, Valeriote FA: Comparison of the dose- and time-survival curves for normal hematopoietic and lymphoma colony-forming cells exposed to vinblastine, vincristine, arabinosylcytosine, and amethopterin. J Natl Cancer Inst 42: 1015–1023, 1969.

    Google Scholar 

  3. Wheeler GP, Alexander JA: Duration of inhibition of synthesis of DNA in tumors and host tissues after single doses of nitrosoureas. Cancer Res 34: 1957–1964, 1974.

    Google Scholar 

  4. Tsuboi KK, Kwong LK: Antiproliferative agents and differential survival between normal and cancer cells. Cancer Res 38: 3745–3750, 1978.

    Google Scholar 

  5. Rupniak HT, Paul D: Selective killing of transformed cells by exploitation of their defective cell cycle control by polyamines. Cancer Res 40: 293–297, 1980.

    Google Scholar 

  6. Armstrong RD, Cadman E: 5′-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow. Cancer Res 43: 2525–2528, 1983.

    Google Scholar 

  7. Hromas R, Barlogie B, Swartzendruber D, Drewinko B: Selective protection by anguidine of normal versus transformed cells against 1β-D-arabinofuranosylcytosine and adriamycin. Cancer Res 43: 1135–1137, 1983.

    Google Scholar 

  8. Dresch C, Minc J, Mary JY: In vivo protection of normal mouse hematopoiesis by a β blocking agent during S-phase chemotherapy. Cancer Res 44: 493–497, 1984.

    Google Scholar 

  9. Salmon SE: Human tumor colony assay and chemosensitivity testing. Cancer Treat Rep 68: 117–125, 1984.

    Google Scholar 

  10. Hamburger AW: Use of in vitro tests in predictive cancer chemotherapy. J Natl Cancer Inst 66: 981–988, 1981.

    Google Scholar 

  11. Hart IR, Fidler IJ: The implications of tumor heterogeneity for studies on the biology and therapy of cancer metastasis. Biochim Biophys Acta 651: 37–50, 1981.

    Google Scholar 

  12. Poste G: Experimental systems for analysis of the malignant phenotype. Cancer Metastasis Rev 1: 141–199, 1982.

    Google Scholar 

  13. Dexter DL, Calabresi P: Intraneoplastic diversity. Biochim Biophys Acta 695: 97–112, 1982.

    Google Scholar 

  14. De Vita VTJr: The relationship between tumor mass and resistance to chemotherapy. Cancer 51: 1209–1220, 1983.

    Google Scholar 

  15. Fidler IJ: Recent concepts of cancer metastasis and their implications for therapy. Cancer Treat Rep 68: 193–198, 1984.

    Google Scholar 

  16. Skipper HE, Schabel FMJr: Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect. Cancer Treat Rep 68: 43–61, 1984.

    Google Scholar 

  17. Fidler IJ, Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science 197: 893–895, 1977.

    Google Scholar 

  18. Talmadge JE, Fidler IJ: Cancer metastasis is selective or random depending on the parent tumour population. Nature 297: 593–594, 1982.

    Google Scholar 

  19. Poste G, Fidler IJ: The pathogenesis of cancer metastasis. Nature 283: 139–146, 1980.

    Google Scholar 

  20. Barranco SC, Ho DHW, Drewinko B, Romsdahl MM, Humphrey RM: Differential sensitivities of human melanoma cells grown in vitro to arabinosylcytosine. Cancer Res 32: 2733–2736, 1972.

    Google Scholar 

  21. Heppner GH, Dexter DL, De Nucci T, Miller FR, Calabresi P: Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res 38: 3758–3763, 1978.

    Google Scholar 

  22. Lotan R, Nicolson GL: Heterogeneity in growth inhibition by β-trans-retinoic acid of metastatic B16 melanoma clones and in vivo-selected cell variant lines. Cancer Res 39: 4767–4771, 1979.

    Google Scholar 

  23. Siracký J: An approach to the problem of heterogeneity of human tumour-cell populations. Br J Cancer 39: 570–577, 1979.

    Google Scholar 

  24. Biörklund A, Håkansson L, Stenstam B, Tropé C, Åkerman M: On heterogeneity of non-Hodgkin's lymphomas as regards sensitivity to cytostatic drugs: an in vitro study. Eur J Cancer 16: 647–654, 1980.

    Google Scholar 

  25. Tsuruo T, Fidler IJ: Differences in drug sensitivity among tumor cells from parental tumors, selected variants, and spontaneous metastases. Cancer Res 41: 3058–3064, 1981.

    Google Scholar 

  26. Yung W-KA, Shapiro JR, Shapiro WR: Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res 42: 992–998, 1982.

    Google Scholar 

  27. Miller BE, Miller FR, Heppner GH: Interactions between tumor subpopulations affecting their sensitivity to the antineoplastic agents cyclophosphamide and methotrexate. Cancer Res 41: 4378–4381, 1981.

    Google Scholar 

  28. Willis RA: The spread of tumours in the human body. Butterworths, London, 1973, pp 71–85.

    Google Scholar 

  29. Hauschka TS, Levan A: Cytologic and functional characterisation of single cell clones isolated from the Krebs-2 and Ehrlich ascites tumors. J Natl Cancer Inst 21: 77–135, 1958.

    Google Scholar 

  30. Isaka H: Variable drug sensitivity and chromosomal features of a cancer clone. Gann 56: 443–460, 1965.

    Google Scholar 

  31. Isaka H, Satoh H: Heterogeneity of cancer cell population with respect to natural drug resistance of constituent cells. Gann 55: 155–161, 1964.

    Google Scholar 

  32. Hasegawa Y, Irikura T, Mizuno D: Establishment and characteristics of a brain-passaged subline of Ehrlich carcinoma. Gann 62: 545–548, 1971.

    Google Scholar 

  33. Valeriote F, Van Putten L: Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res 35: 2619–2630, 1975.

    Google Scholar 

  34. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733, 1979.

    Google Scholar 

  35. Fugmann RA, Anderson JC, Stolfi RL, Martin DS: Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors. Cancer Res 37: 496–500, 1977.

    Google Scholar 

  36. Poste G, Doll J, Fidler IJ: Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. Proc Natl Acad Sci USA 78: 6226–6230, 1981.

    Google Scholar 

  37. Poste G, Tzeng J, Doll J, Greig R, Rieman D, Zeidman I: Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. Proc Natl Acad Sci USA 79: 6574–6578, 1982.

    Google Scholar 

  38. Cifone MA, Fidler IJ: Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci USA 78: 6949–6952, 1981.

    Google Scholar 

  39. Loeb LA, Springgate CF, Battula N: Errors in DNA replication as a basis of malignant changes. Cancer Res 34: 2311–2321, 1974.

    Google Scholar 

  40. Norton L, Simon R: Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61: 1307–1317, 1977.

    Google Scholar 

  41. Leventhal BG, Levine AS, Graw RGJr, Simon R, Freireich EJ, Henderson ES: Long-term second remissions in acute lymphatic leukemia. Cancer 35: 1136–1140, 1975.

    Google Scholar 

  42. Bodey GP, Freireich EJ, Gehan E, McCredie KB, Rodriguez V, Gutterman J, Burgess MA: Late intensification therapy for acute leukemia in remission. JAMA 235: 1021–1025, 1976.

    Google Scholar 

  43. Goldin A, Venditti JM, Humphreys SR, Mantel N: Influence of the concentration of leukemic inoculum on the effectiveness of treatment. Science 123: 840, 1956.

    Google Scholar 

  44. Sato H: Experimental studies on the mechanism of metastasis formation. Acta Pathol Jpn 9 (suppl): 685–706, 1959.

    Google Scholar 

  45. Sato H: Cancer metastasis and ascites tumors. Natl Cancer Inst Monogr 16: 241–261, 1984.

    Google Scholar 

  46. Mulder JH, Bignell C, Van Putten LM: Tumour load dependent effectiveness of cyclophosphamide in Lewis lung carcinoma. In: Hellmann K, Hilgard P, Eccles S (eds) Metastasis: clinical and experimental aspects. Martinus Nijhoff, The Hague, 1980, pp 432–435.

    Google Scholar 

  47. Slack NH, Bross IDJ: The influence of site of metastasis on tumour growth and response to chemotherapy. Br J Cancer 32: 78–86, 1975.

    Google Scholar 

  48. Harper PG, Souhami RL, Spiro SG, Geddes DM, Guimaraes M, Fearon F, Smyth JF: Tumor size, response rate, and prognosis in small cell carcinoma of the bronchus treated by combination chemotherapy. Cancer Treat Rep 66: 463–470, 1982.

    Google Scholar 

  49. Skipper HE, Schabel FMJr, Wilcox WS: Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with ‘curability’ of experimental leukemia. Cancer Chemother Rep 35: 1–111, 1964.

    Google Scholar 

  50. De Wys WD: A quantitative model for the study of the growth and treatment of a tumor and its metastases with correlation between proliferative state and sensitivity to cyclophosphamide. Cancer Res 32: 367–373, 1972.

    Google Scholar 

  51. De Wys WD: Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res 32: 374–379, 1972.

    Google Scholar 

  52. Steel GG, Adams K: Stem-cell survival and tumor control in the Lewis lung carcinoma. Cancer Res 35: 1530–1535, 1975.

    Google Scholar 

  53. Steel GG, Adams K, Stanley J: Size dependence of the response of Lewis lung tumors to BCNU. Cancer Treat Rep 60: 1743–1748, 1976.

    Google Scholar 

  54. Abe I, Sato S: Cell population size dependency of therapeutic effect of divided dosage of 1-β-D-arabinofuranosylcytosine. Gann 67: 461–464, 1976.

    Google Scholar 

  55. Schabel FMJr: The use of tumor growth kinetics in planning ‘curative’ chemotherapy of advanced solid tumors. Cancer Res 29: 2384–2389, 1969.

    Google Scholar 

  56. Schabel FMJr: Concepts for systemic treatment of micrometastases. Cancer 35: 15–24, 1975.

    Google Scholar 

  57. Rabes HM: Cell kinetics of primary and metastatic solid human tumors. In: Lapis K, Jeney A, Price MR (eds) Tumour progression and markers. Kugler, Amsterdam, 1982, pp 83–90.

    Google Scholar 

  58. Schabel FMJr, Skipper HE, Trader MW, Wilcox WS: Experimental evaluation of potential anticancer agents. XIX. Sensitivity of nondividing leukemic cell populations to certain classes of drugs in vivo. Cancer Chemother Rep 48: 17–30, 1965.

    Google Scholar 

  59. Bhuyan BK, Fraser TJ, Day KJ: Cell proliferation kinetics and drug sensitivity of exponential and stationary populations of cultured L1210 cells. Cancer Res 37: 1057–1063, 1977.

    Google Scholar 

  60. Simpson-Herren L, Sanford AH, Holmquist JP: Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep 60: 1749–1760, 1976.

    Google Scholar 

  61. Ohl S, Schüning F, Schmidt CG: Growth inhibition of simulated metastases by a large primary tumor. In: Hellmann K, Hilgard P, Eccles S (eds) Metastasis: clinical and experimental aspects. Martinus Nijhoff, The Hague, 1980, pp 65–68.

    Google Scholar 

  62. Sugarbaker EV, Thornthwaite J, Ketcham AS: Inhibitory effect of a primary tumor on metastasis. In: Day SB, Myers WPL, Stansly P, Garattini S, Lewis MG (eds) Cancer invasion and metastasis: biologic mechanisms and therapy. Raven, New York, 1977, pp 227–240.

    Google Scholar 

  63. Gunduz N, Fisher B, Saffer EA: Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 39: 3861–3865, 1979.

    Google Scholar 

  64. Fisher B, Gunduz N, Saffer EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43: 1488–1492, 1983.

    Google Scholar 

  65. Houghton PJ, Tew KD, Taylor DM: Some studies on the distribution and effects of cyclophosphamide (NSA-26271) in normal and neoplastic tissues. Cancer Treat Rep 60: 459–464, 1976.

    Google Scholar 

  66. Donelli MG, Colombo T, Broggini M, Garattini S: Differential distribution of antitumor agents in primary and secondary tumors. Cancer Treat Rep 61: 1319–1324, 1977.

    Google Scholar 

  67. Abe I, Suzuki M, Sato H: Effects of proteolytic enzymes on selective increase of drug concentration in tumor tissue. J Med Enzymol 3: 87–92, 1978.

    Google Scholar 

  68. Chen H-SG, Gross JF: Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses. Cancer Treat Rep 64: 31–40, 1980.

    Google Scholar 

  69. Kaplan WD, Ensminger WD, Come SE, Smith EH, D'Orsi CJ, Levin DC, Takvorian RW, Steele GDJr: Radionuclide angiography to predict patient response to hepatic artery chemotherapy. Cancer Treat Rep 64: 1217–1222, 1980.

    Google Scholar 

  70. Taniguchi S, Baba T: ‘Two route chemotherapy’ using cis-diamminedichloroplatinum (II) and its antidote, sodium thiosulfate, for peritoneally disseminated cancer in rats. Gann 73: 475–479, 1982.

    Google Scholar 

  71. Sagiyama K, Uozumi J, Aoki K, Baba T: Efficacy of ‘tworoute chemotherapy’ using intra-arterial cisplatin and iv sodium thiosulfate, its antidote, in rat bladder tumor. Cancer Treat Rep 67: 567–572, 1983.

    Google Scholar 

  72. Ensminger WD, Gyves JW: Regional cancer chemotherapy. Cancer Treat Rep 68: 101–115, 1984.

    Google Scholar 

  73. Révész L: Effect of tumour cells killed by X-rays upon the growth of admixed viable cells. Nature 178: 1391–1392. 1956.

    Google Scholar 

  74. Dykes DJ, Griswold DPJr, Schabel FMJr: Growth support of small B16 melanoma implants with nitrosourea-sterilized fractions of the same tumor. Cancer Res 36: 2031–2034, 1976.

    Google Scholar 

  75. Abe I, Hori K, Saito S, Suzuki M, Sato H: Effect of attenuated cells on the growth of small implant of Yoshida ascites hepatoma AH109A. Tohoku J Exp Med 134: 385–392, 1981.

    Google Scholar 

  76. De Wys WD, Mansky JM: Delayed hematological recovery after cyclophosphamide treatment in the presence of an advanced tumor. Cancer Res 33: 2662–2667, 1973.

    Google Scholar 

  77. Goldin A: Potential for selective inhibition of metastasis. In: Hellmann K, Hilgard P, Eccles S (eds) Metastasis: clinical and experimental aspects. Martinus Nijhoff, The Hague, 1980, pp 427–431.

    Google Scholar 

  78. Gimbrone MAJr, Gullino PM: Angiogenic capacity of preneoplastic lesions of the murine mammary gland as a marker of neoplastic transformation. Cancer Res 36: 2611–2620, 1976.

    Google Scholar 

  79. Maiorana A, Gullino PM: Acquisition of angiogenic capacity and neoplastic transformation in the rat mammary gland. Cancer Res 38: 4409–4414, 1978.

    Google Scholar 

  80. Ziche M, Gullino PM: Angiogenesis and neoplastic progression in vitro. J Natl Cancer Inst 69: 483–487, 1982.

    Google Scholar 

  81. Folkman J.: Tumor angiogenesis factor. Cancer Res 34: 2109–2113, 1974.

    Google Scholar 

  82. Folkman J, Tyler K: Tumor angiogenesis: its possible role in metastasis and invasion. In: Day SB, Myers WPL, Stansly P, Garattini S, Lewis MG (eds) Cancer invasion and metastasis. Raven, New York, 1977, pp 95–103.

    Google Scholar 

  83. Warren BA: Tumor angiogenesis. In: Peterson H-I (ed) Tumor blood circulation. CRC, New York, 1979, pp 49–75.

    Google Scholar 

  84. Shubik P: Vascularization of tumors: a review. J Cancer Res Clin Oncol 103: 211–226, 1982.

    Google Scholar 

  85. Greenblatt M, Shubik P: Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J Natl Cancer Inst 41: 111–124, 1968.

    Google Scholar 

  86. Alessandri G, Raju K, Gullino PM: Mobilization of capillary endothelium in vitro induced by effectors of angiogenesis in vivo. Cancer Res 43: 1790–1797, 1983.

    Google Scholar 

  87. Raju KS, Alessandri G, Gullino PM: Characterization of a chemoattractant for endothelium induced by angiogenesis effectors. Cancer Res 44: 1579–1584, 1984.

    Google Scholar 

  88. Fenselau A, Watt S, Mello RJ: Tumor angiogenic factor: purification from the Walker 256 rat tumor. J Biol Chem 256: 9605–9611, 1981.

    Google Scholar 

  89. Weiss JB, Brown RA, Kumar S, Phillips P: An angiogenic factor isolated from tumours: a potent low-molecular-weight compound. Br J Cancer 40: 493–496, 1979.

    Google Scholar 

  90. Ziche M, Jones J, Gullino PM: Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst 69: 475–482, 1982.

    Google Scholar 

  91. McAuslan BR, Hoffman H: Endothelium stimulating factor from Walker carcinoma cells: relation to tumor angiogenic factors. Exp Cell Res 119: 181–190, 1979.

    Google Scholar 

  92. Folkman J: Angiogenesis: initiation and control. Ann NY Acad Sci 401: 212–227, 1982.

    Google Scholar 

  93. Nicosia RF, Tchao R, Leighton J: Angiogenesis-dependent tumor spread in reinforced fibrin clot culture. Cancer Res 43: 2159–2166, 1983.

    Google Scholar 

  94. Yamaura H, Sato H: Quantitative studies on the developing vascular system of rat hepatoma. J Natl Cancer Inst 53: 1229–1240, 1974.

    Google Scholar 

  95. Yamaura H, Sato H: Experimental studies on angiogenesis in AH109A ascites tumor tissue transplanted to a transparent chamber in rats. In: Garattini S, Franchi G (eds) Chemotherapy of cancer dissemination and metastasis. Raven, New York, 1973, pp 149–175.

    Google Scholar 

  96. Yamaura H, Matsuzawa T, Sato H: Development of tumor vascular system and the regrowth after irradiation: morphometric study by transparent chamber technique. In: Tsuchiya M, Asano M, Oda M (eds) Basic aspects of microcirculation. Excerpta Medica, Amsterdam, 1982, pp 177–189.

    Google Scholar 

  97. Nakadate T, Suzuki M, Sato H: Quantitative study on the liberation of tumor cells into the circulating blood, Gann 70: 435–446, 1979.

    Google Scholar 

  98. Groothuis DR, Pasternak F, Fischer JM, Bigner DD, Vick NA: Spatial distribution of proliferating cells in avian sarcoma virus-induced gliomas. Cancer Res 43: 456–459, 1983.

    Google Scholar 

  99. Vaupel P: Hypoxia in neoplastic tissue. Microvasc Res 13: 399–408, 1977.

    Google Scholar 

  100. Thomlinson RH, Gray LH: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9: 539–549, 1955.

    Google Scholar 

  101. Tannock IF: The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumor. Br J Cancer 22: 258–273, 1968.

    Google Scholar 

  102. Hirst DG, Denekamp J: Tumour cell proliferation in relation to the vasculature. Cell Tissue Kinet 12: 31–42, 1979.

    Google Scholar 

  103. Gullino PM, Grantham FH: Studies on the exchange of fluids between host and tumor. II. The blood flow of hepatomas and other tumors in rats and mice. J Natl Cancer Inst 27: 1465–1491, 1961.

    Google Scholar 

  104. Cataland S, Cohen C, Sapirstein LA: Relationship between size and perfusion rate of transplanted tumors. J Natl Cancer Inst 29: 389–394, 1962.

    Google Scholar 

  105. Peterson H-I: Tumor blood flow compared with normal tissue blood flow. In: Peterson H-I (ed) Tumor blood circulation. CRC, New York, 1979, pp 103–114.

    Google Scholar 

  106. Suzuki M, Hori K, Abe I, Saito S, Sato H: Characteristic function in microcirculation of tumors. Cancer Metastasis Rev 3: 115–126, 1984.

    Google Scholar 

  107. Suzuki M, Hori K, Abe I, Saito S, Sato H: Characteristics of microcirculation in tumor. Jpn J Cancer Chemother 6 (suppl 2): 287–291, 1979.

    Google Scholar 

  108. Suzuki M, Hori K, Abe I, Saito S, Sato H: Characteristic microcirculation of tumor. J Jpn Coll Angiol 19: 233–236, 1979.

    Google Scholar 

  109. Suzuki M, Hori K, Abe I, Saito S, Sato H: Experimental study on characteristics of microcirculation in tumor tissue, with reference to cancer chemotherapy. In: Hellman K, Hilgard P, Eccles S (eds) Metastasis: clinical and experimental aspects. Martinus Nijhoff, The Hague, 1980, pp 356–360.

    Google Scholar 

  110. Suzuki M, Hori K, Abe I, Saito S, Sato H: A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 67: 663–669, 1981.

    Google Scholar 

  111. Suzuki M, Hori K, Abe I, Saito S, Sato H: Functional characteristics of tumor vessels, with reference to enhancement of drug delivery. Jpn J Cancer Clin 28: 592–598, 1982.

    Google Scholar 

  112. Groothuis DR, Pasternak JF, Fischer JM, Blasberg RG, Gigner DD, Vick NA: Regional measurements of blood flow in experimental RG-2 rat gliomas. Cancer Res 43: 3362–3367, 1983.

    Google Scholar 

  113. Karlsson I, Alpsten M, Appelgren KL, Peterson H-I: Intratumor distribution of blood flow and of vascular volume in a transplantable rat sarcoma. J Cancer Res Clin Oncol 98: 213–219, 1980.

    Google Scholar 

  114. Tannock IF, Steel GG: Quantitative techniques for study of the anatomy and function of small blood vessels in tumors. J Natl Cancer Inst 42: 771–782, 1969.

    Google Scholar 

  115. Endrich B, Reinhold HA, Gross JF, Intaglietta M: Tissue perfusion inhomogeneity during early tumor growth in rats. J Natl Cancer Inst 62: 387–395, 1979.

    Google Scholar 

  116. Hultborn R, Tveit E, Weiss L: Vascular reactivity and perfusion characteristics in 7,12-dimethylbenz-(a)anthracene-induced rat mammary neoplasia. Cancer Res 43: 363–366, 1983.

    Google Scholar 

  117. Jirtle R, Clifton KH: On carcinoma growth and vascular supply: a study of mouse mammary tumor strain MTG-B. Proc Soc Exp Biol Med 138: 267–269, 1971.

    Google Scholar 

  118. Hori K, Suzuki M, Abe I, Saito S, Sato H: Increase in tumor microvascular pressure by angiotensin-induced hypertension: implication for pharmacokinetic analysis of drug delivery into tumor tissue. Jpn J Cancer Chemother 10: 953–960, 1983.

    Google Scholar 

  119. Weiss L, Hultborn R, Tveit E: Blood flow characteristics in induced rat mammary neoplasia. Microvasc Res 17: S119, 1979.

  120. Kaelin WGJr, Shrivastav S, Jirtle RL: Blood flow to primary tumors and lymph node metastases in SMT-2A tumor-bearing rats following intravenous flunarizine. Cancer Res 44: 896–899, 1984.

    Google Scholar 

  121. Gullino PM, Grantham FH: Studies on the exchange of fluids between host and tumor. III. Regulation of blood flow in hepatomas and other rat tumors. J Natl Cancer Inst 28: 211–229, 1962.

    Google Scholar 

  122. Kruuv JA, Inch WR, McCredie JA: Blood flow and oxygenation of tumors in mice. I. Effects of breathing gases containing carbon dioxide at atmospheric pressure. Cancer 20: 51–59, 1967.

    Google Scholar 

  123. Kaelin WGJr, Shrivastav S, Shand DG, Jirtle RL: Effect of verapamil on malignant tissue blood flow in SMT-2A tumor-bearing rats. Cancer Res 42: 3944–3949, 1982.

    Google Scholar 

  124. Sato H, Kato K, Sato Y, Mimata Y, Asamura M, Kanamaru R, Wakui A, Suzuki M, Sato H: Clinical study on selective enhancement of drug delivery by angiotensin II in cancer chemotherapy. In: Hellmann K, Hilgard P, Eccles S (eds) Metastasis: clinical and experimental aspects. Martinus Nijhoff, The Hague, 1980, pp 388–394.

    Google Scholar 

  125. Sato H, Sato K, Sato Y, Asamura M, Kanamaru R, Sugiyama Z, Kitahara T, Mimata Y, Wakui A, Suzuki M, Hori K, Abe I, Saito S, Sato H: Induced hypertension chemotherapy of cancer patients by selectieve enhancement of drug delivery to tumor tissue with angiotensin II. Sci Rep Res Inst Tohoku Univ-C 28: 32–44, 1981.

    Google Scholar 

  126. Sato H, Sato K, Sato Y, Asamura M, Kanamaru R, Mimata Y, Wakui A: Clinical cancer chemotherapy based on the experimental findings of selective enhancement of drug delivery to tumor tissue by angiotensin II. Jpn J Cancer Chemother 8 (suppl): 91–100, 1981.

    Google Scholar 

  127. Wakui A, Suzuki M: Cancer chemotherapy in combination with angiotensin-induced hypertension. Jpn J Cancer Chemother 10: 1577–1583, 1983.

    Google Scholar 

  128. Underwood JCE, Carr I: The ultrastructure and permeability characteristics of the blood vessels of a transplantable rat sarcoma. J Pathol 107: 157–166, 1972.

    Google Scholar 

  129. Cater DB, Taylor CR: Inflammatory changes in tumour vessels after systemic 5-hydroxytryptamine, bradykinin, kallikrein, or lysolecithin. Br J Cancer 20: 517–525, 1966.

    Google Scholar 

  130. Sato H, Suzuki M, Yamaura H: Study on tissue permeability to drugs and chemotherapeutic effect. J Jpn Soc Cancer Ther 4 (suppl 15): 43–49, 1969.

    Google Scholar 

  131. Sato H, Suzuki M, Yamaura H, Abe I: Metastasis of cancer. Diagn Ther 57: 1766–1770, 1969.

    Google Scholar 

  132. Suzuki M, Abe I, Sato H: Experimental studies on the effects of proteases in cancer chemotherapy, with reference to the permeability in tumor tissue. Saishin-Igaku 28: 920–925, 1973.

    Google Scholar 

  133. Sato H, Abe I, Suzuki M: Metastasis and chemotherapy in cancer. Jpn J Cancer Chemother 2: 725–732, 1980.

    Google Scholar 

  134. Blasberg RG, Kobayashi T, Patlak CS, Shinohara M, Miyoaka M, Rice JM, Shapiro WR: Regional blood flow, capillary permeability, and glucose utilization in two brain tumor models: preliminary observations and pharmacokinetic implications. Cancer Treat Rep 65 (suppl 2): 3–12, 1981.

    Google Scholar 

  135. Groothuis DR, Fischer JM, Pasternak JF, Blasberg RG, Vick NA, Bigner DD: Regional measurements of bloodto-tissue transport in experimental RG-2 rat gliomas. Cancer Res 43: 3368–3373, 1983.

    Google Scholar 

  136. Suzuki M, Abe I, Sato H: Changes in drug delivery (by blood-brain barrier dysfunction) on arachnoid leukemia: implication for CNS leukemic dissemination. Clin Exp Metastasis 1: 163–171, 1983.

    Google Scholar 

  137. Neuwelt EA, Hill SA, Frenkel EP, Diehl JT, Maravilla KR, Vu LH, Clark WK, Rapoport S, Barnett PA, Lewis SE, Ehle AL, Beyer CWJr: Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase 1 trial in patients with malignant brain tumors. Cancer Treat Rep 65 (suppl 2): 39–43, 1981.

    Google Scholar 

  138. Groothuis DR, Fischer JM, Vick NA, Bigner DD: Comparative permeability of different glioma models to horseradish peroxidase. Cancer Treat Rep 65 (suppl 2): 13–18, 1981.

    Google Scholar 

  139. Hata J, Akatsuka A, Sato T, Tamaoki N: Ultrastructural studies on tumor angiogenesis. In: Tsuchiya M, Asano M, Oda M (eds) Basic aspects of microcirculation. Excerpta Medica. Amsterdam, 1981, pp 166–176.

    Google Scholar 

  140. Straw JA, Hart MM, Klubes P, Zaharko DS, Dedrick RL: Distribution of anticancer agents in spontaneous animal tumors. I. Regional blood flow and methotrexate distribution in canine lymphosarcoma. J Natl Cancer Inst 52: 1327–1331, 1974.

    Google Scholar 

  141. Casley-Smith JR: Blood capillary/interstitial tissue/lymphatic relationships and interactions: the structure and functioning of the blood vessels, interstitial tissues, and lymphatics. In: Földi M, Casley-Smith JR (eds) Lymphangiology. FK Schattauer, Stuttgart, 1983, pp 136–164.

    Google Scholar 

  142. Butler TP, Grantham FH, Gullino PM: Bulk transfer of fluid in the interstitial compartment of mammary tumors. Cancer Res 35: 3084–3088, 1975.

    Google Scholar 

  143. Hori K, Suzuki M, Abe I, Saito S, Sato H: Change in pressure difference between intra- and extravascular space in tumor tissue by angiotensin-induced hypertension. In: Proceedings of the 41st annual meeting of the Japanese Cancer Association, Osaka. Tokyo: Japanese Cancer Association, 1982, p 234.

    Google Scholar 

  144. Swabb EA, Wei J, Gullino PM: Diffusion and convection in normal and neoplastic tissues. Cancer Res 34: 2814–2822, 1974.

    Google Scholar 

  145. Wolf RA, Chaung L-Y, Muller JE, Kloner RA, Braunwald E: Intravenous bovine testicular hyaluronidase depolymerizes myocardial hyaluronic acid in dogs with coronary artery occlusion. Circ Res 47: 88–95, 1980.

    Google Scholar 

  146. Nugent LJ, Jain RK: Extravascular diffusion in normal and neoplastic tissues. Cancer Res 44: 238–244, 1984.

    Google Scholar 

  147. Wiig H, Tveit E, Hultborn R, Weiss L: Interstitial and vascular pressures in rat mammary tumors. Bibl Anat 20: 620–623, 1981.

    Google Scholar 

  148. Vaupel PW, Frinak S, Bicher HI: Heterogeneous oxygen partial pressure and pH distribution in C3H mouse mammary adenocarcinoma. Cancer Res 41: 2008–2013, 1981.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Experimental Oncology, Research Institute for Tuberculosis and Cancer, Tohoku University, 4-1 Seiryomachi, 980, Sendai, Japan

    Ikuo Abe, Maroh Suzuki, Katsuyoshi Hori, Sachiko Saito & Haruo Sato

Authors
  1. Ikuo Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maroh Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katsuyoshi Hori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sachiko Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Haruo Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abe, I., Suzuki, M., Hori, K. et al. Some aspects of size-dependent differential drug response in primary and metastatic tumors. Cancer Metast Rev 4, 27–39 (1985). https://doi.org/10.1007/BF00047735

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00047735

Keywords

Search

Navigation